Lacidipine is a calcium antagonist of the dihydropyridine group that is highly selective for
vascular tissues. It has been tested during the last few years for the treatment of arterial …

Eleven centers in Tuscany, Italy, recruited 96 patients (aged 21-75 years) with mild-to-
moderate essential hypertension [diastolic blood pressure (DBP) 95-115 mm Hg; systolic …

Synopsis Lacidipine is an orally administered calcium channel blocker of the
dihydropyridine class, which shows selectivity for vascular smooth muscle over cardiac …

In an open, multicenter study, the calcium antagonist lacidipine was tested for efficacy and
safety, particularly with respect to any influence on lipid and carbohydrate metabolism. The …

The clinical safety of the new dihydropyridine calcium antagonist lacidipine was assessed in
14 clinical trials, including 1,372 patients treated with lacidipine and 687 treated with an …

Calcium channel blockers are increasingly used in the treatment of hypertension. Newer
calcium channel blockers of the dihydropyridine group have longer elimination half-lives …

Arterial hypertension is a chronic condition regarded as one of the main risk factors for
development of coronary atherosclerosis. As dyslipidemia and reduced glucose tolerance …

The effect of lacidipine, a dihydropyridine calcium antagonist on lipid metabolism, has been
followed in 8 patients with uncomplicated mild to moderate essential hypertension treated …

The clinical safety of lacidipine, a new dihydropyridine calcium antagonist, has been
assessed in a longterm, comparative study in hypertensive patients. Slowrelease (SR) …

The aim of this study was to compare the antihypertensive efficacy and tolerability of
lacidipine, a new dihydropyridine calcium antagonist, and slow-release nifedipine (SR) in …